Atwater Malick LLC Sells 1,668 Shares of Novo Nordisk A/S (NYSE:NVO)

Atwater Malick LLC lowered its position in Novo Nordisk A/S (NYSE:NVO) by 1.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 166,832 shares of the company’s stock after selling 1,668 shares during the quarter. Novo Nordisk A/S comprises approximately 6.4% of Atwater Malick LLC’s investment portfolio, making the stock its 2nd biggest holding. Atwater Malick LLC’s holdings in Novo Nordisk A/S were worth $19,865,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in NVO. Bank of New Hampshire boosted its holdings in shares of Novo Nordisk A/S by 1,356.8% in the first quarter. Bank of New Hampshire now owns 13,257 shares of the company’s stock valued at $1,702,000 after acquiring an additional 12,347 shares in the last quarter. Cim LLC bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $23,547,000. Burford Brothers Inc. bought a new position in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $1,045,000. Fox Hill Wealth Management boosted its holdings in shares of Novo Nordisk A/S by 121.3% in the first quarter. Fox Hill Wealth Management now owns 28,320 shares of the company’s stock valued at $3,636,000 after acquiring an additional 15,525 shares in the last quarter. Finally, Cetera Investment Advisers boosted its holdings in shares of Novo Nordisk A/S by 453.3% in the first quarter. Cetera Investment Advisers now owns 265,538 shares of the company’s stock valued at $34,095,000 after acquiring an additional 217,545 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Up 2.1 %

Shares of NYSE:NVO traded up $2.51 during mid-day trading on Friday, hitting $120.04. The stock had a trading volume of 4,115,753 shares, compared to its average volume of 4,325,323. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The company has a market cap of $538.68 billion, a PE ratio of 41.11, a P/E/G ratio of 1.53 and a beta of 0.42. Novo Nordisk A/S has a 12-month low of $92.94 and a 12-month high of $148.15. The company’s 50 day moving average is $129.39 and its 200-day moving average is $132.00.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.65 EPS for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a net margin of 34.86% and a return on equity of 87.43%. The firm had revenue of $9.82 billion during the quarter, compared to analysts’ expectations of $9.91 billion. On average, sell-side analysts predict that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The business also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Shareholders of record on Friday, August 16th were given a $0.5126 dividend. The ex-dividend date of this dividend was Friday, August 16th. This represents a yield of 0.7%. Novo Nordisk A/S’s payout ratio is 24.66%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on NVO shares. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $170.00 to $160.00 and set an “outperform” rating for the company in a report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $145.17.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.